Eosinophilic esophagitis: New molecules, better life?

Area of Science:

• Immunology
• Gastroenterology
• Allergy

Background:

• Eosinophilic esophagitis (EoE) is a T helper type 2 (Th2)-associated inflammatory disorder increasingly recognized as a common cause of esophageal symptoms.
• Current EoE management includes dietary elimination, proton-pump inhibitors (PPIs), and topical corticosteroids, all with limitations in efficacy or accessibility.
• There are no approved EoE therapies in the US, and limited options in Europe and Canada.

Purpose of the Study:

• To review established and emerging medical therapies for EoE.
• To focus on novel treatments targeting specific molecular pathways in EoE pathogenesis.
• To discuss how these new therapies may alter future EoE management.

Main Methods:

• Literature review of established and emerging EoE therapies.
• Analysis of pathophysiological insights driving new treatment development.
• Focus on molecular targets and their therapeutic potential.

Main Results:

• EoE pathogenesis understanding has spurred the development of targeted therapies.
• New treatments focus on molecular targets crucial for disease progression.
• These advancements are poised to significantly change EoE treatment strategies.

Conclusions:

• Targeted therapies represent a significant advancement in EoE treatment.
• Understanding EoE pathophysiology is key to developing effective interventions.
• The next decade is expected to bring transformative changes in EoE management.